Free Trial

Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these companies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consistently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Senseonics stock logo

1. Senseonics NYSE:SENS

$0.45 -0.01 (-1.52%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. More about Senseonics

Market Capitalization
$367.42 million
P/E Ratio
-3.47
Consensus Rating
Buy
Consensus Price Target
$1.54 (+239.4% Upside)
Volume
3.65 million shares
Average Volume
7.89 million shares
Plus Therapeutics stock logo

2. Plus Therapeutics NASDAQ:PSTV

$0.43 +0.01 (+2.74%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. More about Plus Therapeutics

Market Capitalization
$42.39 million
P/E Ratio
-0.19
Consensus Rating
Buy
Consensus Price Target
$7.88 (+1,744.3% Upside)
Volume
4.21 million shares
Average Volume
17.94 million shares
Context Therapeutics stock logo

3. Context Therapeutics NASDAQ:CNTX

$0.98 +0.01 (+1.12%)
As of 01:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context Therapeutics

Market Capitalization
$87.82 million
P/E Ratio
-2.72
Consensus Rating
Buy
Consensus Price Target
$5.20 (+431.2% Upside)
Volume
140,802 shares
Average Volume
195,715 shares
Reviva Pharmaceuticals stock logo

4. Reviva Pharmaceuticals NASDAQ:RVPH

$0.28 +0.01 (+5.40%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva Pharmaceuticals

Market Capitalization
$19.49 million
P/E Ratio
-0.43
Consensus Rating
Buy
Consensus Price Target
$5.33 (+1,798.0% Upside)
Volume
11.12 million shares
Average Volume
1.92 million shares
i-80 Gold stock logo

5. i-80 Gold NYSE:IAUX

$0.96 +0.01 (+0.63%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

i-80 Gold Corp. is a mining company, engages in the exploration, development and production of gold and silver mineral deposits principally in the United States. More about i-80 Gold

Market Capitalization
$780.14 million
P/E Ratio
-2.66
Consensus Rating
Moderate Buy
Consensus Price Target
$1.50 (+56.9% Upside)
Volume
4.71 million shares
Average Volume
5.98 million shares
Carisma Therapeutics stock logo

6. Carisma Therapeutics NASDAQ:CARM

$0.28 +0.03 (+13.95%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. More about Carisma Therapeutics

Market Capitalization
$11.91 million
P/E Ratio
-0.18
Consensus Rating
Moderate Buy
Consensus Price Target
$1.93 (+575.4% Upside)
Volume
976,013 shares
Average Volume
8.00 million shares
Sangamo Therapeutics stock logo

7. Sangamo Therapeutics NASDAQ:SGMO

$0.55 +0.00 (+0.38%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. More about Sangamo Therapeutics

Market Capitalization
$165.04 million
P/E Ratio
-1.89
Consensus Rating
Moderate Buy
Consensus Price Target
$4.50 (+721.2% Upside)
Volume
2.54 million shares
Average Volume
5.91 million shares
Canaan stock logo

8. Canaan NASDAQ:CAN

$0.76 -0.02 (-2.49%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Canaan Inc engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. More about Canaan

Market Capitalization
$283.03 million
P/E Ratio
-0.84
Consensus Rating
Moderate Buy
Consensus Price Target
$2.50 (+229.4% Upside)
Volume
28.76 million shares
Average Volume
27.50 million shares
PLAYSTUDIOS stock logo

9. PLAYSTUDIOS NASDAQ:MYPS

$0.99 0.00 (-0.17%)
As of 01:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PLAYSTUDIOS, Inc develops and publishes free-to-play casual games for mobile and social platforms in the United States and internationally. More about PLAYSTUDIOS

Market Capitalization
$124.47 million
P/E Ratio
-4.14
Consensus Rating
Hold
Consensus Price Target
$2.50 (+151.8% Upside)
Volume
125,031 shares
Average Volume
236,113 shares
Applied Therapeutics stock logo

10. Applied Therapeutics NASDAQ:APLT

$0.48 +0.04 (+9.96%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. More about Applied Therapeutics

Market Capitalization
$68.69 million
P/E Ratio
-1.06
Consensus Rating
Hold
Consensus Price Target
$4.13 (+763.0% Upside)
Volume
1.06 million shares
Average Volume
2.41 million shares
Oncobiologics stock logo

11. Oncobiologics NASDAQ:OTLK

$0.95 -0.02 (-1.66%)
As of 01:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. More about Oncobiologics

Market Capitalization
$42.07 million
P/E Ratio
-1.66
Consensus Rating
Hold
Consensus Price Target
$7.00 (+639.2% Upside)
Volume
826,011 shares
Average Volume
1.59 million shares
Fate Therapeutics stock logo

12. Fate Therapeutics NASDAQ:FATE

$0.99 +0.03 (+3.09%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. More about Fate Therapeutics

Market Capitalization
$114.41 million
P/E Ratio
-0.68
Consensus Rating
Hold
Consensus Price Target
$3.30 (+232.7% Upside)
Volume
777,841 shares
Average Volume
1.96 million shares
Sutro Biopharma stock logo

13. Sutro Biopharma NASDAQ:STRO

$0.89 +0.01 (+0.83%)
As of 01:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. More about Sutro Biopharma

Market Capitalization
$75.79 million
P/E Ratio
-0.35
Consensus Rating
Hold
Consensus Price Target
$4.47 (+399.6% Upside)
Volume
73,127 shares
Average Volume
1.18 million shares
Adaptimmune Therapeutics stock logo

14. Adaptimmune Therapeutics NASDAQ:ADAP

$0.17 +0.02 (+16.34%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. More about Adaptimmune Therapeutics

Market Capitalization
$44.53 million
P/E Ratio
-0.26
Consensus Rating
Hold
Consensus Price Target
$1.35 (+704.6% Upside)
Volume
132.18 million shares
Average Volume
25.85 million shares
Leslie's stock logo

15. Leslie's NASDAQ:LESL

$0.33 +0.05 (+18.23%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Leslie's, Inc operates as a direct-to-consumer pool and spa care brand in the United States. The company markets and sells pool and spa supplies and related products and services. More about Leslie's

Market Capitalization
$61.62 million
P/E Ratio
-0.74
Consensus Rating
Reduce
Consensus Price Target
$1.60 (+381.9% Upside)
Volume
2.46 million shares
Average Volume
4.65 million shares
Exro Technologies stock logo

16. Exro Technologies OTCMKTS:EXROF

$0.02 0.00 (0.00%)
As of 09/19/2025

Exro Technologies Inc focuses on developing generation power-control electronics in Canada. The company offers Exro Coil Driver, which allows the motor to switch between different operational profiles in real-time, as well as have multiple gears for scooters, electric bikes, recreational, light electric cars, motorcycles, fleet vans, electric buses, passenger vehicles, long-haul trucks, and industrial vehicles markets; and Exro Cell Driver, a stationary energy storage system for commercial and industrial energy storage applications. More about Exro Technologies

Market Capitalization
$9.97 million
P/E Ratio
-0.04
Consensus Rating
Reduce
Average Volume
1.03 million shares
Today's Range
$0.0174
$0.0174
50-Day Range
$0.01
$0.06